Identification

Name
Triptorelin
Accession Number
DB06825
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.

Structure
Thumb
Synonyms
  • (6-D-Tryptophan)luteinizing hormone-releasing hormone
  • (D-Trp6)-GnRH
  • Luteinizing hormone-releasing factor (pig), 6-D-tryptophan
  • pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
  • triptorelina
  • triptoreline
  • triptorelinum
External IDs
AY-25650 / CL 118,532 / CL-118532 / WY-42462
Product Ingredients
IngredientUNIICASInChI Key
Triptorelin acetate43OFW291R9140194-24-7HPPONSCISKROOD-OYLNGHKZSA-N
Triptorelin pamoate08AN7WA2G0124508-66-3ZBVJFYPGLGEMIN-OYLNGHKZSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DecapeptylSolution0.1 mgSubcutaneousFerring Pharmaceuticals2012-08-09Not applicableCanada
TrelstarKitActavis Pharma Company2010-03-11Not applicableUs
TrelstarKitAllergan2001-06-29Not applicableUs
TrelstarInjection, powder, for suspension, extended release22.5 mgIntramuscularAllergan Pharma Co.2013-10-16Not applicableCanada
TrelstarKitAllergan2000-06-15Not applicableUs
TrelstarInjection, powder, lyophilized, for suspension22.5 mg/2mLIntramuscularActavis Pharma Company2010-03-11Not applicableUs
TrelstarInjection, powder, lyophilized, for suspension3.75 mg/2mLIntramuscularActavis Pharma Company2000-06-15Not applicableUs
TrelstarKitAllergan2010-03-11Not applicableUs
TrelstarInjection, powder, for suspension, extended release3.75 mgIntramuscularAllergan Pharma Co.2005-12-15Not applicableCanada
TrelstarKitActavis Pharma Company2001-06-29Not applicableUs
International/Other Brands
Diphereline (Ferring Pharmaceuticals) / Gonapeptyl (Ferring Pharmaceuticals) / Variopeptyl (Varian Darou Pajooh)
Categories
UNII
9081Y98W2V
CAS number
57773-63-4
Weight
Average: 1311.473
Monoisotopic: 1310.630874772
Chemical Formula
C64H82N18O13
InChI Key
VXKHXGOKWPXYNA-PGBVPBMZSA-N
InChI
InChI=1S/C64H82N18O13/c1-34(2)23-46(56(88)75-45(13-7-21-69-64(66)67)63(95)82-22-8-14-52(82)62(94)72-31-53(65)85)76-58(90)48(25-36-28-70-42-11-5-3-9-40(36)42)78-57(89)47(24-35-15-17-39(84)18-16-35)77-61(93)51(32-83)81-59(91)49(26-37-29-71-43-12-6-4-10-41(37)43)79-60(92)50(27-38-30-68-33-73-38)80-55(87)44-19-20-54(86)74-44/h3-6,9-12,15-18,28-30,33-34,44-52,70-71,83-84H,7-8,13-14,19-27,31-32H2,1-2H3,(H2,65,85)(H,68,73)(H,72,94)(H,74,86)(H,75,88)(H,76,90)(H,77,93)(H,78,89)(H,79,92)(H,80,87)(H,81,91)(H4,66,67,69)/t44-,45-,46-,47-,48+,49-,50-,51-,52-/m0/s1
IUPAC Name
(2S)-N-[(2S)-5-carbamimidamido-1-[(2S)-2-[(carbamoylmethyl)carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]-2-[(2R)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-indol-3-yl)propanamido]-4-methylpentanamide
SMILES
CC(C)C[[email protected]](NC(=O)[[email protected]@H](CC1=CNC2=CC=CC=C12)NC(=O)[[email protected]](CC1=CC=C(O)C=C1)NC(=O)[[email protected]](CO)NC(=O)[[email protected]](CC1=CNC2=C1C=CC=C2)NC(=O)[[email protected]](CC1=CNC=N1)NC(=O)[[email protected]@H]1CCC(=O)N1)C(=O)N[[email protected]@H](CCCNC(N)=N)C(=O)N1CCC[[email protected]]1C(=O)NCC(N)=O

Pharmacology

Indication

Triptorelin is indicated for the palliative treatment of advanced prostate cancer.

Structured Indications
Pharmacodynamics

The first administration of triptorelin is followed by a transient surge of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol,and testosterone. The time, peak and decline of testosterone in the body varies depending on the dose administered. This initial surge is often responsible for worsening of prostate cancer symptoms such as urethral or bladder outlet obstruction, bone pain, spinal cord injury and hematuria in the early stages. A sustained decrease in FSH and LH, and significant reduction of testicular steroidogenesis is usually seen 2-4 weeks post-initiation of therapy. This result is a reduction of serum testosterone to levels which are typically seen in surgically castrated men. Ultimately, tissues and functions that require these hormones become inactive. The effects of triptorelin can usually be reversed once the drug is discontinued.

Mechanism of action

Triptorelin is a synthetic agonist analog of gonadotropin releasing hormone (GnRH). Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone.

TargetActionsOrganism
AGonadotropin-releasing hormone receptor
agonist
Human
Absorption

Following IV administration of triptorelin, triptorelin is completely absorbed.

Volume of distribution

After a single IV dose of 0.5mg, the volume of distribution of triptorelin peptide in healthy males was 30 - 33L.

Protein binding

Triptorelin does not bind to plasma proteins at clinically relevant concentrations.

Metabolism

The metabolism of triptorelin in humans is not well understood; however, metabolism likely does not involve hepatic enzymes such as cytochrome P450. Whether or not triptorelin affects, or how it affects other metabolizing enzymes is also poorly understood. Triptorelin has no identified metabolites.

Route of elimination

Elimination of triptorelin involves both the kidneys and the liver.

Half life

The pharmacokinetics of triptorelin follows a 3 compartment model. The half lives are estimated to be 6 minutes, 45 minutes, and 3 hours respectively.

Clearance

In healthy male volunteers, total clearance of triptorelin was 211.9 mL/min.

Toxicity

Some of the most commonly reported adverse effects of triptorelin are hot flushes reported in 58.6% of patients, skeletal pain in 12.1%, impotence in 7.1%, and headache in 5.0%. Other reported adverse effects include injection site pain, general body pain, leg pain, fatigue, hypertension, dizziness, diarrhea, vomiting, insomnia, emotional lability, anemia, pruritus, urinary tract infections, and urinary retention. Triptorelin is classified as Pregnancy Category X and contraindicated in pregnant women or in women who may become pregnant. Hormonal changes caused by triptorelin increase the risk for pregnancy loss. Studies done on pregnant rats demonstrated maternal toxicity and embryo-fetal toxicities.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Triptorelin.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Triptorelin.Approved, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Triptorelin.Investigational, Withdrawn
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Triptorelin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Triptorelin.Experimental
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Triptorelin.Experimental, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Triptorelin.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Triptorelin.Approved
AmiodaroneTriptorelin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AnagrelideTriptorelin may increase the QTc-prolonging activities of Anagrelide.Approved
Arsenic trioxideTriptorelin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTriptorelin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineTriptorelin may increase the QTc-prolonging activities of Asenapine.Approved
AzithromycinTriptorelin may increase the QTc-prolonging activities of Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Triptorelin.Investigational
BedaquilineTriptorelin may increase the QTc-prolonging activities of Bedaquiline.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Triptorelin.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Triptorelin.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Triptorelin.Investigational, Withdrawn
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Triptorelin.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.Approved
Capromab pendetideTriptorelin may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Triptorelin.Experimental
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Triptorelin.Experimental
CeritinibTriptorelin may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineTriptorelin may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineTriptorelin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Triptorelin.Approved
Choline C 11The therapeutic efficacy of Choline C 11 can be decreased when used in combination with Triptorelin.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Triptorelin.Experimental
CiprofloxacinTriptorelin may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideTriptorelin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramTriptorelin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinTriptorelin may increase the QTc-prolonging activities of Clarithromycin.Approved
ClozapineTriptorelin may increase the QTc-prolonging activities of Clozapine.Approved
Corifollitropin AlfaThe therapeutic efficacy of Corifollitropin Alfa can be increased when used in combination with Triptorelin.Approved
CrizotinibTriptorelin may increase the QTc-prolonging activities of Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Triptorelin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Triptorelin.Experimental
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Triptorelin.Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Triptorelin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Triptorelin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Triptorelin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Triptorelin.Approved
DisopyramideTriptorelin may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Triptorelin.Approved, Investigational
DofetilideTriptorelin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronTriptorelin may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneTriptorelin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DronedaroneTriptorelin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolTriptorelin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Triptorelin.Approved
EliglustatTriptorelin may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.Approved
ErythromycinTriptorelin may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramTriptorelin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Triptorelin.Approved, Investigational
FlecainideTriptorelin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluoxetineTriptorelin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolTriptorelin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
Gadobenic acidTriptorelin may increase the QTc-prolonging activities of Gadobenic acid.Approved
GemifloxacinTriptorelin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Triptorelin.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Triptorelin.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Triptorelin.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Triptorelin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Triptorelin.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Triptorelin.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Triptorelin.Approved
GoserelinTriptorelin may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronTriptorelin may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Triptorelin.Investigational
HaloperidolTriptorelin may increase the QTc-prolonging activities of Haloperidol.Approved
IbutilideTriptorelin may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneTriptorelin may increase the QTc-prolonging activities of Iloperidone.Approved
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Triptorelin.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Triptorelin.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Triptorelin.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Triptorelin.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Triptorelin.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Triptorelin.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Triptorelin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Triptorelin.Experimental
LenvatinibTriptorelin may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideTriptorelin may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevofloxacinTriptorelin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Triptorelin.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Triptorelin.Approved
LopinavirTriptorelin may increase the QTc-prolonging activities of Lopinavir.Approved
LumefantrineTriptorelin may increase the QTc-prolonging activities of Lumefantrine.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Triptorelin.Approved
MethadoneTriptorelin may increase the QTc-prolonging activities of Methadone.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Triptorelin.Experimental
MifepristoneMifepristone may increase the QTc-prolonging activities of Triptorelin.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Triptorelin.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Triptorelin.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Triptorelin.Approved, Investigational
MoxifloxacinTriptorelin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Triptorelin.Approved, Investigational
NilotinibTriptorelin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
OfloxacinTriptorelin may increase the QTc-prolonging activities of Ofloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Triptorelin.Experimental, Investigational
OndansetronTriptorelin may increase the QTc-prolonging activities of Ondansetron.Approved
OuabainOuabain may decrease the cardiotoxic activities of Triptorelin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Triptorelin.Approved, Vet Approved
PaliperidoneTriptorelin may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatTriptorelin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PazopanibTriptorelin may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidineTriptorelin may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenTriptorelin may increase the QTc-prolonging activities of Perflutren.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Triptorelin.Experimental
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Triptorelin.Approved, Investigational, Withdrawn
PimozideTriptorelin may increase the QTc-prolonging activities of Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Triptorelin.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Triptorelin.Approved, Investigational
PrimaquineTriptorelin may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideTriptorelin may increase the QTc-prolonging activities of Procainamide.Approved
PromazineTriptorelin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneTriptorelin may increase the QTc-prolonging activities of Propafenone.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Triptorelin.Experimental
QuetiapineTriptorelin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineTriptorelin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineTriptorelin may increase the QTc-prolonging activities of Quinine.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Triptorelin.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Triptorelin.Approved, Investigational
SaquinavirTriptorelin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Triptorelin.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Triptorelin.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Triptorelin.Investigational
SotalolTriptorelin may increase the QTc-prolonging activities of Sotalol.Approved
SulfisoxazoleTriptorelin may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Triptorelin.Approved, Investigational
TelavancinTriptorelin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinTriptorelin may increase the QTc-prolonging activities of Telithromycin.Approved
TetrabenazineTriptorelin may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineTriptorelin may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Triptorelin.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Triptorelin.Approved
ToremifeneTriptorelin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Triptorelin.Approved, Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Triptorelin.Investigational, Withdrawn
VandetanibTriptorelin may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibTriptorelin may increase the QTc-prolonging activities of Vemurafenib.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Triptorelin.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Triptorelin.Approved, Investigational
ZiprasidoneTriptorelin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolTriptorelin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Lahlou N, Carel JC, Chaussain JL, Roger M: Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000 Jul;13 Suppl 1:723-37. [PubMed:10969915]
  2. Padula AM: GnRH analogues--agonists and antagonists. Anim Reprod Sci. 2005 Aug;88(1-2):115-26. [PubMed:15955640]
External Links
KEGG Drug
D06247
PubChem Compound
25074470
PubChem Substance
310264898
ChemSpider
17290424
ChEBI
63633
ChEMBL
CHEMBL1201334
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Triptorelin
ATC Codes
L02AE04 — Triptorelin
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (691 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingBasic ScienceInfertility, Female1
1, 2RecruitingTreatmentAdenocarcinoma, Prostate / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1
2Active Not RecruitingTreatmentBreast Cancer Invasive Nos1
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedDiagnosticSystemic Lupus Erythematosus (SLE)1
2CompletedTreatmentInfertilities / Poor Ovarian Response2
2CompletedTreatmentProstate Cancer1
2RecruitingPreventionCancer, Breast1
2RecruitingSupportive CareAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
2RecruitingTreatmentCancers / Prostate Cancer1
2RecruitingTreatmentProstate Cancer1
2RecruitingTreatmentSalivary Gland Cancers1
2RecruitingTreatmentSubfertility1
2TerminatedSupportive CareCancer, Breast / Hormone Changes / Therapeutic Agent Toxicity1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / HER2-Negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer1
2TerminatedTreatmentProstate Cancer1
2, 3CompletedPreventionAlkylating Agents / Fertility Preservation / Malignant Lymphomas1
2, 3RecruitingTreatmentCastration-resistant Prostate Cancer Patients With Oligometastases1
3Active Not RecruitingTreatmentCancer, Breast2
3Active Not RecruitingTreatmentCancer, Breast / Estrogen Receptor Positive Breast Cancer / Progesterone Receptor Positive Tumor / Recurrent Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer1
3Active Not RecruitingTreatmentProstate Cancer2
3CompletedNot AvailableCancer, Breast / Sleep disorders and disturbances / Tiredness1
3CompletedDiagnosticProstate Cancer1
3CompletedSupportive CareCancer, Breast1
3CompletedSupportive CareBone destruction / Prostate Cancer1
3CompletedTreatmentCentral Precocious Puberty (CPP)1
3CompletedTreatmentControlled Ovarian Stimulation1
3CompletedTreatmentEndometriosis1
3CompletedTreatmentInfertilities3
3CompletedTreatmentInfertilities / Polycystic Ovaries Syndrome1
3CompletedTreatmentProstate Cancer3
3CompletedTreatmentProstatic Neoplasms1
3CompletedTreatmentPuberty, Precocious2
3Not Yet RecruitingTreatmentOvarian Hyperstimulation Syndrome1
3RecruitingTreatmentEndometriosis1
3RecruitingTreatmentProstate Cancer1
3TerminatedNot AvailableInfertilities1
3TerminatedTreatmentCancer, Breast1
3Unknown StatusPreventionEndometriosis1
3Unknown StatusTreatmentProstate Cancer3
4Active Not RecruitingTreatmentIdiopathic Short Stature (ISS)1
4Active Not RecruitingTreatmentProstate Cancer1
4CompletedNot AvailableProstate Cancer1
4CompletedTreatmentEndometriosis1
4CompletedTreatmentEndometriosis / Infertilities1
4CompletedTreatmentFatty Liver / Hypogonadism / Metabolic Syndromes / Prostate Cancer1
4CompletedTreatmentInfertilities3
4CompletedTreatmentInfertilities / Premature Ovarian Failure (POF)1
4CompletedTreatmentInfertility Indicated for ICSI1
4CompletedTreatmentInvitro Fertilization1
4CompletedTreatmentOvarian Hyperstimulation Syndrome1
4RecruitingBasic ScienceGender Dysphoria1
4RecruitingSupportive CareInfertilities2
4RecruitingTreatmentEmbryo Transfer / Luteal Support1
4RecruitingTreatmentInfertilities2
4RecruitingTreatmentInfertility, Female1
4TerminatedPreventionOvarian Hyperstimulation Syndrome1
4TerminatedTreatmentAssisted Reproductive Technology therapy1
4TerminatedTreatmentProstate Cancer2
4Unknown StatusDiagnosticCentral Precocious Puberty (CPP) / Sexual Precocity1
4Unknown StatusPreventionCentral Precocious Puberty (CPP)1
4Unknown StatusPreventionOvarian Hyperstimulation Syndrome / Polycystic Ovaries Syndrome1
4Unknown StatusTreatmentInfertilities1
4Unknown StatusTreatmentInfertility, Female / Poor Responder1
Not AvailableActive Not RecruitingNot AvailableDeep Infiltrating Endometriosis (DIE)1
Not AvailableActive Not RecruitingTreatmentEndometriosis / Infertilities1
Not AvailableCompletedNot AvailableImplantation, Embryo / Pregnancy1
Not AvailableCompletedNot AvailableNeonates / Pregnancy1
Not AvailableCompletedSupportive CareHodgkins Disease (HD) / Lymphoma, Hodgkins1
Not AvailableCompletedTreatmentInfertilities3
Not AvailableCompletedTreatmentNormal Oocyte Donors1
Not AvailableCompletedTreatmentUterine Leiomyomas1
Not AvailableEnrolling by InvitationScreeningInfertility, Female / Single Nucleotide Polymorphism,GnRH Receptor, IVF1
Not AvailableNot Yet RecruitingNot AvailableInfertilities1
Not AvailableNot Yet RecruitingNot AvailableProstate Cancer1
Not AvailableNot Yet RecruitingOtherEmbryonic Quality Using MitoScore (DuoStim x Conventional Stimulation Protocol) / Potential Usefulness of the DuoStim Protocol / Rate of Euploid Embryos Per Cycle (DuoStim x Conventional Stimulation Protocol)1
Not AvailableNot Yet RecruitingTreatmentEndometriosis1
Not AvailableNot Yet RecruitingTreatmentInfertilities2
Not AvailableNot Yet RecruitingTreatmentOvulatory Dysfunction / Subfertility, Female1
Not AvailableRecruitingNot AvailableInfertilities1
Not AvailableRecruitingNot AvailableProstate Cancer2
Not AvailableRecruitingTreatmentEndometriotic Cysts1
Not AvailableRecruitingTreatmentProstate Cancer1
Not AvailableUnknown StatusPreventionInfertility and at High Risk of OHSS1
Not AvailableUnknown StatusTreatmentInfertility and at High Risk of OHSS1
Not AvailableUnknown StatusTreatmentWomen With Poor Ovarian Response1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionSubcutaneous0.1 mg
Injection, powder, for suspension, extended releaseIntramuscular11.25 mg
Injection, powder, for suspension, extended releaseIntramuscular22.5 mg
Injection, powder, for suspension, extended releaseIntramuscular3.75 mg
Injection, powder, lyophilized, for suspensionIntramuscular11.25 mg/2mL
Injection, powder, lyophilized, for suspensionIntramuscular22.5 mg/2mL
Injection, powder, lyophilized, for suspensionIntramuscular3.75 mg/2mL
Kit
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5776885No1995-07-072015-07-07Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0305 mg/mLALOGPS
logP1.07ALOGPS
logP-3.6ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)9.49ChemAxon
pKa (Strongest Basic)11.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count18ChemAxon
Polar Surface Area487.92 Å2ChemAxon
Rotatable Bond Count33ChemAxon
Refractivity352.43 m3·mol-1ChemAxon
Polarizability135.23 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as polypeptides. These are peptides containing ten or more amino acid residues.
Kingdom
Organic compounds
Super Class
Organic Polymers
Class
Polypeptides
Sub Class
Not Available
Direct Parent
Polypeptides
Alternative Parents
Peptides / Tyrosine and derivatives / Phenylalanine and derivatives / Histidine and derivatives / Leucine and derivatives / N-acyl-alpha amino acids and derivatives / Proline and derivatives / Tryptamines and derivatives / Serine and derivatives / Alpha amino acid amides
show 23 more
Substituents
Polypeptide / Alpha peptide / Tyrosine or derivatives / Phenylalanine or derivatives / Histidine or derivatives / Leucine or derivatives / N-acyl-alpha amino acid or derivatives / Proline or derivatives / Triptan / Alpha-amino acid amide
show 48 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
oligopeptide (CHEBI:63633)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Peptide binding
Specific Function
Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone...
Gene Name
GNRHR
Uniprot ID
P30968
Uniprot Name
Gonadotropin-releasing hormone receptor
Molecular Weight
37730.355 Da

Drug created on September 14, 2010 10:21 / Updated on November 22, 2017 12:37